BIOADAPTIVES, INC.

Previous wording

The Company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, and healthy weight loss. MyndMed™ provides Immediate cognitive enhancement (focus, clarity, motivation), medium-term resilience and memory gains, and long-term neuroprotection and cognitive health, making it a robust solution for anyone seeking to optimize mental performance and brain longevity. Zeranovia™ is a healthy weight loss enhancer, and Wynovia™ is used to help reduce the loss of lean muscle mass during dieting.

Current wording

The Company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, and healthy weight loss. MyndMed™ provides Immediate cognitive enhancement (focus, clarity, motivation), medium-term resilience and memory gains, and long-term neuroprotection and cognitive health, making it a robust solution for anyone seeking to optimize mental performance and brain longevity. Zeranovia™ is a healthy weight loss enhancer, Xcellara™ is BioAdaptives’ regenerative wellness solution to enhance your performance, accelerate recovery, and revitalize your health.

Previous wording

The Company’s Product MyndMed™ completed its pre-launch phase in November 2025. MyndMed™ is designed to optimize multiple neurotransmitter systems and neuroprotective pathways, delivering broad-spectrum cognitive benefits. By synergistically targeting acetylcholine, dopamine, neuroprotection, synaptic growth, and stress reduction, MyndMed™ supports both immediate and sustained improvements in mental performance, resilience, and brain health. It aids in a rapid increase in motivation, sustained attention, and mental clarity, and helps in tackling demanding cognitive tasks with greater drive and efficiency. The product underwent rigorous testing by TruShield and received its TruShield Certified Certification, which provides the brand with a trusted, science-backed way to demonstrate that the product is free from banned substances.

Current wording

The Company’s Product MyndMed™ completed its pre-launch phase in November 2025. MyndMed™ is designed to optimize multiple neurotransmitter systems and neuroprotective pathways, delivering broad-spectrum cognitive benefits. By synergistically targeting acetylcholine, dopamine, neuroprotection, synaptic growth, and stress reduction, MyndMed™ supports both immediate and sustained improvements in mental performance, resilience, and brain health. It aids in a rapid increase in motivation, sustained attention, and mental clarity, and helps in tackling demanding cognitive tasks with greater drive and efficiency. The product underwent rigorous testing by TruShield and received its TruShield Certified Certification, which provides the brand with a trusted, science-backed way to demonstrate that the product is free from banned substances. Joining MyndMed™™ is MyndRenew.™ a nighttime dietary supplement formulated to support sleep quality and the brain's natural overnight recovery processes. MyndRenew™ is the nighttime component of the Company's MyndSystem™ platform — a first-of-its-kind approach to cognitive support that spans the full 24-hour cycle. This 24-hour MyndSystem platform was launched in the end of this quarter.

Previous wording

Xcellara™ is BioAdaptives’ regenerative wellness solution to enhance your performance, accelerate recovery, and revitalize your health. Backed by double-blind placebo-controlled clinical trials, Xcellara™ activates stem cells for cellular regeneration. Derived from a proprietary blend of nutraceutical compounds, Xcellara™ is the secret weapon for success on and off the court, providing a myriad of benefits. In its market testing, Xcellera™ has demonstrated a positive effect on individuals challenged by chronic fatigue.

Current wording

Xcellara™ BioAdaptives’ regenerative wellness solution to enhance performance, accelerate recovery, and revitalize health is Backed by double-blind placebo-controlled clinical trials, Xcellara™ activates stem cells for cellular regeneration. Derived from a proprietary blend of nutraceutical compounds, Xcellara™ is the secret weapon for success on and off the court, providing a myriad of benefits. In its market testing, Xcellera™ has demonstrated a positive effect on individuals challenged by chronic fatigue. To expand the success and possibilities we see in Xcellara™, a collection of products based on Xcellara™ researches are being expanded into an Xcellara™ platform. The first new product in this Platform is Xcellara-Heart™. The new formula combines the company's stem/progenitor cell mobilization platform with Tanshinone IIA, a compound studied in cardiovascular signaling research. The launch expands BioAdaptives' portfolio of targeted wellness supplements and represents another step in the company's strategy of building products around its Xcellara™ platform. The Company is looking to add another 6 science rich products based on the Xcellara™ platform within the year.

Previous wording

BioAdaptives Inc. has developed a robust Direct to Consumer (DTC) digital marketing campaign to connect directly with its target audience. Leveraging platforms like social media, email marketing, and a user-friendly website, the company promotes its supplement products with engaging content tailored to health-conscious consumers. Through targeted ads, informative blog posts, and compelling calls-to-action, BioAdaptives ensures its messaging resonates, driving awareness and conversions while fostering a community around wellness and natural health solutions.

Current wording

BioAdaptives Inc. has developed a robust Direct to Consumer (DTC) digital marketing campaign to connect directly with its target audience. Leveraging platforms like social media, email marketing, and user-friendly websites, the company promotes its supplement products with engaging content tailored to health-conscious consumers. Through targeted ads, informative blog posts, and compelling calls-to-action, BioAdaptives ensures its messaging resonates, driving awareness and conversions while fostering a community around wellness and natural health solutions.

Previous wording

In June, the Company also placed its PawPa™ Regen™ Dog Treats with Amazon and started limited advertising efforts there. It has shown slow progress.

Current wording

In the past 9 months, the Company also placed its PawPa™ Regen™ Dog Treats with Amazon and started limited advertising efforts there. It has shown slow progress.

Previous wording

We had a net loss of $ 111,086 for the three-month period ended March 31, 2026, which was $ 86,050 less than the net loss of $ 197,136 for the three-month period ended March 31, 2025. The change in our results is mainly due to the Change in operating expenses.

Current wording

We had a net gain of $ 150,090 for the three-month period ended June 30, 2026, which gained $ $308,004 more than the net loss of $ 157914 for the three-month period ended June 30, 2025. The change in our results is mainly due to the Change in the value of derivatives liabilities.

Previous wording

PawPa™ Regen dog treats, started limited sales via its website and Amazon. It is still going through its market testing. ClearMynd™ MyndMed™ started its test marketing in November and is still evolving into its new bundle. While Xcellara™ has not started its marketing yet.

Current wording

PawPa™ Regen dog treats, started limited sales via its website and Amazon. It is still going through its market testing. MyndSystem™ started its test marketing in May and is still evolving into its new bundle. While Xcellara™ has slowly started its marketing

Previous wording

Other Income (Expense) $ 5 and $ - for the three months ended March 31, 2026, and 2025. It also shows a change in fair value of derivative liabilities of 174,884 and 61,659 for March 31, 2026, and 2025.

Current wording

Other Income (Expense) $ 347,266 and $ 121,305 for the three months ended June 30, 2026, and 2025. It also shows a change in fair value of derivative liabilities of 446,739 and 130,954 for June 30, 2026, and 2025.

Previous wording

As a result of our operating expenses the Company reported a net loss of $111,086 and $197.136 for the three months ended March 31, 2026, and 2025

Current wording

As a result of our change in the fair value of the derivatives liabilities the Company reported a net gain of $156,090 and a net loss of $157914 for the three months ended June 30, 2026, and 2025

Previous wording

Our balance sheet as of March 31, 2026 reflects current assets of $ 123,449 , including cash in the amount of $73.606.

Current wording

Our balance sheet as of June 31, 2026 reflects current assets of $ 67,767 , including cash in the amount of $29,221

Previous wording

Net cash provided (used) by operating activities during the nine months ended March 31, 2026 was $84.839 a decrease of $ 13,067 from net cash used of $97,906 in operating activities during the three months ended March 31, 2025

Current wording

Net cash provided (used) by operating activities during the six months ended June 30, 2026 was $129,224 a decrease of $ 79,664 from net cash used of $208,888 in operating activities during the three months ended June 30, 2025

Previous wording

On March 31, 2026, we had $ 73,606 of cash on-hand and an accumulated deficit of $ 1,465,210 , and as noted throughout this report and our financial statements and notes thereto, our independent auditors expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2025. We anticipate to be incurring some losses in the near future, until all the products are launched and have maximized their sales. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means.

Current wording

On June 30 2026, we had $ 29,221 of cash on-hand and an accumulated deficit of $ 10,688,200, and as noted throughout this report and our financial statements and notes thereto, our independent auditors expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2025. We anticipate to be incurring some losses in the near future, until all the products are launched and have maximized their sales. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means.